FLT3 and acute myeloid leukemia: More recently, quizartinib, a selective FLT3-ITD type 2 inhibitor, showed a benefit in terms of OS in a phase 3 trial for patients with FLT3-ITD+ AML (QUANTUM-First trial) [35].